New drug shows promise in preventing deadly blood clot relapses in japanese patients

NCT ID NCT04074187

Completed Disease control Sponsor: Sanofi Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 10, 2026 · Updated 21 times

Summary

This study tested a drug called caplacizumab in 21 Japanese adults with acquired thrombotic thrombocytopenic purpura (aTTP), a rare condition causing dangerous blood clots. The goal was to see if the drug could prevent the disease from coming back. Participants received the drug alongside standard plasma exchange treatment, and researchers tracked recurrences, safety, and recovery markers.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Investigational Site Number 3920001

Kitakyushu-Shi, Japan
Investigational Site Number 3920002

Kumamoto, Japan
Investigational Site Number 3920003

Kurashiki-Shi, Japan
Investigational Site Number 3920005

Maebashi, Japan
Investigational Site Number 3920006

Sendai, Japan
Investigational Site Number 3920007

Kashihara-shi, Japan
Investigational Site Number 3920009

Iruma-Gun, Japan
Investigational Site Number 3920010

Kyoto, Japan
Investigational Site Number 3920011

Osaka, Japan
Investigational Site Number 3920013

Kawasaki-Shi, Japan
Investigational Site Number 3920014

Kanazawa, Japan
Investigational Site Number 3920015

Nagoya, Japan

Conditions

Explore the condition pages connected to this study.

THROMBOTIC THROMBOCYTOPENIC PURPURA